Efficacy and Safety of Oral Febuxostat in Participants With Gout

Takeda2,269 enrolled

Overview

The purpose of this study is to compare the efficacy and safety of febuxostat, once Daily (QD), to allopurinol in subjects with hyperuricemia and gout.

Renal impairment is common in subjects with gout, with the prevalence ranging from 50% to 70%. This population represents an unmet medical need as uricosuric drugs are contraindicated in these patients, and the only available treatment, allopurinol, may have to be dose reduced to avoid overt side effects. Febuxostat (TMX-67) is a non-purine selective xanthine oxidase inhibitor being developed as an orally administered agent for management of hyperuricemia in patients with gout. Treatment duration will be 6 months.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

2,269

Conditions

Gout

Interventions

FebuxostatDRUG

Febuxostat 40 mg, capsules, orally, once daily for up to 6 months.

FebuxostatDRUG

Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.

AllopurinolDRUG

Allopurinol 200 mg or 300 mg, capsules, orally, once daily for up to 6 months. Dose is dependent on the subject's renal function. Subjects with normal renal function or mild renal impairment received 300 mg once daily; subjects with moderate renal impairment received 200 mg once daily.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Has one or more of the American Rheumatism Association criteria for the diagnosis of gout. * Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study. * Must have a serum urate level greater than or equal to 8.0 milligram per deciliter (mg/dL). Exclusion Criteria: * Have a severe, unstable, or life threatening medical condition that would likely prevent them from completing this study. * Has a known body reaction to febuxostat, allopurinol, naproxen, any other non-steroidal anti-inflammatory drug (NSAID), aspirin, lansoprazole, colchicine, or any components in their formulation. * History of xanthinuria. * Alcohol consumption greater than 14/week. * History of significant concomitant illness. * Active liver or peptic ulcer disease. * Has rheumatoid arthritis requiring treatment. * Has estimated creatinine clearance less than 30 milliliter per minute (mL/min) calculated using the Cockcroft-Gault formula corrected for ideal body weight. * Requires therapy with any other urate-lowering drug other than the study drug; long-term use of NSAIDs and COX-2 inhibitors; salicylates; thiazide diuretics; losartan; azathioprine; mercaptopurine; theophylline; intravenous (IV) colchicine; cyclosporine; cyclophosphamide; pyrazinamide; sulfamethoxazole;trimethoprim.

Locations (258)

Outcomes

Primary Outcomes

Percentage of Subjects Whose Serum Urate Level is <6.0 Milligrams Per Deciliter (mg/dL) at the Final Visit.

The percentage of subjects whose serum urate level was \<6.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate value was collected.

Time frame: Last Visit on treatment (up to 6 months)

Secondary Outcomes

Percentage of Renal Impairment Subjects Whose Final Visit Serum Urate Level is <6.0 mg/dl

The percentage of subjects with mild-to-moderate renal impairment whose serum urate was \<6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected.

Time frame: Last Visit on treatment (up to 6 months)

Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 2 Visit.

Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 2 visit was summarized.

Time frame: Month 2

Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 4 Visit.

Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 4 visit was summarized.

Time frame: Month 4

Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 6 Visit.

Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 6 visit was summarized.

Time frame: Month 6

Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 2 Visit.

Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was \<5.0 mg/dL at the Month 2 visit was summarized.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

Birmingham, Alabama, United States

Unnamed facility

Hoover, Alabama, United States

Unnamed facility

Hueytown, Alabama, United States

Unnamed facility

Huntsville, Alabama, United States

Unnamed facility

Mobile, Alabama, United States

Unnamed facility

Montgomery, Alabama, United States

Unnamed facility

Northport, Alabama, United States

Unnamed facility

Ozark, Alabama, United States

Unnamed facility

Tuscaloosa, Alabama, United States

Unnamed facility

Chandler, Arizona, United States

...and 248 more locations

Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 4 Visit.

Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was \<5.0 mg/dL at the Month 4 visit was summarized.

Time frame: Month 4

Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 6 Visit.

Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was \<5.0 mg/dL at the Month 6 visit was summarized.

Time frame: Month 6

Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Final Visit.

The percentage of subjects whose serum urate level was \<5.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected.

Time frame: Last Visit on treatment (up to 6 months)

Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 2 Visit

Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was \<4.0 mg/dL at the Month 2 visit was summarized.

Time frame: Month 2

Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 4 Visit

Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was \<4.0 mg/dL at the Month 4 visit was summarized.

Time frame: Month 4

Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 6 Visit

Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was \<4.0 mg/dL at the Month 6 visit was summarized.

Time frame: Month 6

Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Final Visit

The percentage of subjects whose serum urate level was \<4.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected.

Time frame: Last Visit on treatment (up to 6 months)

Mean Percent Change From Baseline in Serum Urate Levels at Month 2 Visit.

Serum urate values were obtained at the Month 2 visit. The percent change in serum urate from baseline to the Month 2 visit was summarized.

Time frame: Baseline and Month 2

Mean Percent Change From Baseline in Serum Urate Levels at Month 4 Visit

Serum urate values were obtained at the Month 4 visit. The percent change in serum urate from baseline to the Month 4 visit was summarized.

Time frame: Baseline and Month 4

Mean Percent Change From Baseline in Serum Urate Levels at Month 6 Visit.

Serum urate values were obtained at the Month 6 visit. The percent change in serum urate from baseline to the Month 6 visit was summarized.

Time frame: Baseline and Month 6

Mean Percent Change From Baseline in Serum Urate Levels at Final Visit.

The percent change in serum urate from baseline to the Final visit was summarized. The final visit was the last visit at which a serum urate value was collected.

Time frame: Baseline and Last Visit on treatment (up to 6 months)